Silexion Therapeutics Q3 net loss narrows 24% year over year to $2.5 million

PUBT · 1d ago
Silexion Therapeutics Q3 net loss narrows 24% year over year to $2.5 million
  • Silexion Therapeutics’ third-quarter 2026 net loss narrowed 24% year over year to $2.53 million.
  • Research and development expenses fell 41% year over year to $1.29 million in the quarter.
  • Cash and cash equivalents totaled $4.76 million at September 30, 2026, with shareholders’ equity of $2.97 million.
  • The first patient received SIL204 in its Phase 2/3 pancreatic cancer trial; additional Israeli and German sites are expected in coming months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130903PRIMZONEFULLFEED1001303515) on November 13, 2026, and is solely responsible for the information contained therein.